New hope for hard-to-treat ovarian cancer: BL-B01D1 enters phase 3 trial
NCT ID NCT06994195
First seen May 02, 2026 · Last updated May 02, 2026
Summary
This phase 3 trial tests whether the experimental drug BL-B01D1 works better than standard chemotherapy for people with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based treatment. About 384 adults who have had 1-3 prior treatments will be randomly assigned to receive either BL-B01D1 or a standard chemo chosen by their doctor. The main goals are to see if the drug delays cancer growth and helps people live longer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY PERITONEAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, China
Contact
Conditions
Explore the condition pages connected to this study.